Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492534 | 0.92 | LMNA (0.37) | MAPTTRPV4BDKRB1NPC1RAB9A | |
| SCHEMBL492458 | 0.92 | MAPT (0.38) | MAPTTRPV4BDKRB1NPC1RAB9A | |
| SCHEMBL493098 | 0.91 | OPRL1 (0.38) | OPRL1BDKRB1NPC1RAB9ANPSR1 | |
| SCHEMBL493055 | 0.90 | OPRL1 (0.39) | OPRL1NPC1RAB9AALDH1A1 | |
| SCHEMBL492558 | 0.90 | HTR7 (0.35) | OPRL1TRPV4BDKRB1OPRM1 | |
| SCHEMBL492545 | 0.89 | BDKRB1 (0.39) | OPRL1BDKRB1NPC1RAB9ANPSR1 | |
| SCHEMBL493332 | 0.88 | BDKRB1 (0.36) | OPRL1TRPV4BDKRB1OPRM1 | |
| SCHEMBL492686 | 0.83 | ALDH1A1 (0.41) | OPRL1BDKRB1ALDH1A1 | |
| SCHEMBL492948 | 0.82 | LMNA (0.37) | MAPTBDKRB1NPC1RAB9ANPSR1 | |
| SCHEMBL492490 | 0.82 | MAPT (0.39) | OPRL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | OPRL1 4/4885MAPT 1653/4885TRPV4 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.